P. Kelly Marcom

5.3k citations

49 papers · 1.8k indexed · h-index 20

Oncology top 2%
Cancer Research top 2%
Molecular Biology
Genetics top 10%
Radiology, Nuclear Medicine and Imaging top 5%

Co-authors: Eric P. Winer Harold J. Burstein Clifford A. Hudis Jeffrey R. Marks Peter C. Ungaro Donald A. Berry Diana Lake Hyman B. Muss
Topics: Breast Cancer Treatment Studies (22 papers)Cancer Treatment and Pharmacology (13 papers)Advanced Breast Cancer Therapies (10 papers)
Cited by: Cancer Research Oncology Reproductive Medicine
Journals: JAMA Journal of Clinical Oncology Cancer Research
Partner nations: United States Germany Canada

In The Last Decade

P. Kelly Marcom

47 papers receiving 1.8k citations

Peers

Countries citing papers authored by P. Kelly Marcom

Since Specialization

Citations

This map shows the geographic impact of P. Kelly Marcom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Kelly Marcom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Kelly Marcom more than expected).

Fields of papers citing papers by P. Kelly Marcom

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Kelly Marcom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Kelly Marcom. The network helps show where P. Kelly Marcom may publish in the future.

Co-authorship network of co-authors of P. Kelly Marcom

This figure shows the co-authorship network connecting the top 25 collaborators of P. Kelly Marcom. A scholar is included among the top collaborators of P. Kelly Marcom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Kelly Marcom. P. Kelly Marcom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Local–regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial) 2019 ·Breast Cancer Research and Treatment ·Jennifer R. Bellon,Hao Guo,William T. Barry,Chau T. Dang,Denise A. Yardley,Beverly Moy,P. Kelly Marcom,Kathy S. Albain,Hope S. Rugo,Matthew J. Ellis,Antonio C. Wolff,Lisa A. Carey,Beth Overmoyer,Ann H. Partridge,Clifford A. Hudis,Ian E. Krop,Harold J. Burstein,Eric P. Winer,Sara M. Tolaney	24
2	Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set 2018 ·Breast Cancer Research and Treatment ·(unknown),Ashirbani Saha,Michael R. Harowicz,Jeffrey R. Marks,P. Kelly Marcom,Maciej A. Mazurowski	134
3	Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype 2018 ·Clinical Breast Cancer ·Jeremy Force,Lynn Howie,Sara Abbott,Rex C. Bentley,P. Kelly Marcom,Gretchen Kimmick,Kelly Westbrook,Sarah Sammons,(unknown),(unknown),Ryan Emerson,Gloria Broadwater,Terry Hyslop,Kimberly Blackwell,Smita K. Nair	22
4	Can algorithmically assessed MRI features predict which patients with a preoperative diagnosis of ductal carcinoma in situ are upstaged to invasive breast cancer? 2017 ·Journal of Magnetic Resonance Imaging ·Michael R. Harowicz,Ashirbani Saha,Lars J. Grimm,P. Kelly Marcom,Jeffrey R. Marks,E. Shelley Hwang,Maciej A. Mazurowski	23
5	Adherence to Recommended Risk Management among Unaffected Women with a BRCA Mutation 2016 ·Journal of Genetic Counseling ·Adam H. Buchanan,Corrine I. Voils,Joellen M. Schildkraut,(unknown),Nora Horick,P. Kelly Marcom,(unknown),Celette Sugg Skinner	28
6	Recurrence-free survival in breast cancer is associated with MRI tumor enhancement dynamics quantified using computer algorithms 2015 ·European Journal of Radiology ·Maciej A. Mazurowski,Lars J. Grimm,Jing Zhang,P. Kelly Marcom,Sora C. Yoon,Connie Kim,Sujata V. Ghate,Karen S. Johnson	27
7	Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial) 2015 ·Breast Cancer Research and Treatment ·Kathryn J. Ruddy,Hao Guo,William T. Barry,Chau T. Dang,Denise A. Yardley,Beverly Moy,P. Kelly Marcom,Kathy S. Albain,Hope S. Rugo,Matthew J. Ellis,Iuliana Shapira,Antonio C. Wolff,Lisa A. Carey,Beth Overmoyer,Clifford A. Hudis,Ian E. Krop,Harold J. Burstein,Eric P. Winer,Ann H. Partridge,Sara M. Tolaney	49
8	Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers 2014 ·Clinical Cancer Research ·Mark Jesus M. Magbanua,Lisa A. Carey,Amy DeLuca,Jimmy Hwang,Janet H. Scott,Mothaffar F. Rimawi,Erica L. Mayer,P. Kelly Marcom,Minetta C. Liu,Francisco J. Esteva,John W. Park,Hope S. Rugo	32
9	Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort 2013 ·Annals of Surgical Oncology ·Rachel A. Greenup,Adam H. Buchanan,Wendy Lorizio,(unknown),Salina Chan,Tracey P. Leedom,(unknown),Jane McLennan,(unknown),P. Kelly Marcom,E. Shelley Hwang	170
10	Abstract S4-03: Exome sequencing reveals clinically actionable mutations in the pathogenesis and metastasis of triple negative breast cancer 2013 ·Cancer Research ·(unknown),E.P. Hamilton,P. Kelly Marcom,(unknown),Novera Herbert Spector,Gretchen Kimmick,(unknown),Justin Favaro,Gifone Aguiar Rocha,(unknown),Christopher G. Love,Paula Scotland,(unknown)	3
11	Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC) 2013 ·Cancer Research ·SM Tolaney,(unknown),(unknown),DA Yardley,Beverly Moy,P. Kelly Marcom,KS Albain,HS Rugo,Matthew J. Ellis,Iuliana Shapira,Antonio C. Wolff,LA Carey,(unknown),AH Partridge,Hao Guo,(unknown),IE Krop,HJ Burstein,EP Winer	22
12	Abstract P4-09-01: Retrospective evaluation of precision of gene-expression-based signatures of prognosis and tumor biology in replicate surgical biospecimens from patients with breast cancer 2012 ·Cancer Research ·(unknown),P. Kelly Marcom,Joseph Geradts,(unknown)	1
13	Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing 2011 ·Clinical Cancer Research ·Christina I. Herold,Vijaya Chadaram,Bercedis L. Peterson,P. Kelly Marcom,Judith O. Hopkins,Gretchen Kimmick,Justin Favaro,Erika Hamilton,(unknown),Sarah Bacus,Kimberly Blackwell	64
14	Lower-Dose vs High-Dose Oral Estradiol Therapy of Hormone Receptor–Positive, Aromatase Inhibitor–Resistant Advanced Breast Cancer 2009 ·JAMA ·Matthew J. Ellis,Feng Gao,Farrokh Dehdashti,Donna B. Jeffe,P. Kelly Marcom,Lisa A. Carey,Maura N. Dickler,Paula Silverman,Gini F. Fleming,A. Kommareddy,(unknown),Robert J. Crowder,Barry A. Siegel	204
15	Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840 2008 ·Journal of Clinical Oncology ·Andrew D. Seidman,Donald A. Berry,Constance Cirrincione,Lyndsay N. Harris,Hyman B. Muss,P. Kelly Marcom,(unknown),Harold J. Burstein,Diana Lake,Charles L. Shapiro,Peter C. Ungaro,Larry Norton,Eric P. Winer,Clifford A. Hudis	446
16	Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel 2008 ·Cancer Treatment Reviews ·Minetta C. Liu,George D. Demetri,Donald A. Berry,Larry Norton,Gloria Broadwater,Nicholas J. Robert,David B. Duggan,Daniel F. Hayes,I. Craig Henderson,Alan P. Lyss,Judith O. Hopkins,Peter A. Kaufman,P. Kelly Marcom,Jerry Younger,Nancy U. Lin,Katherine H. R. Tkaczuk,Eric P. Winer,Clifford A. Hudis	11
17	TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer 2008 ·Journal of Clinical Oncology ·LA Carey,Hope S. Rugo,P. Kelly Marcom,William Irvin,Madlyn Ferraro,Emily Burrows,Xiaping He,Charles M. Perou,Eric P. Winer	133
18	A Pilot Study of Predictive Markers of Chemotherapy-Related Amenorrhea Among Premenopausal Women with Early Stage Breast Cancer 2008 ·Cancer Investigation ·Carey K. Anders,P. Kelly Marcom,Bercedis L. Peterson,Lin Gu,(unknown),(unknown),(unknown),Gretchen Kimmick,Heather Shaw,Stacey A. Snyder,Monica Antenos,Teresa K. Woodruff,Kimberly Blackwell	96
19	Gene Expression Profiles of Multiple Breast Cancer Phenotypes and Response to Neoadjuvant Chemotherapy 2006 ·Clinical Cancer Research ·Holly K. Dressman,Christopher Hans,Andrea H. Bild,John A. Olson,Eric L. Rosen,P. Kelly Marcom,Vlayka Liotcheva,Ellen L. Jones,Željko Vujašković,Jeffrey R. Marks,Mark W. Dewhirst,Mike West,Joseph R. Nevins,Kimberly Blackwell	121
20	Phase I study of Doxil and vinorelbine in metastatic breast cancer 1999 ·Annals of Oncology ·Harold J. Burstein,(unknown),William P. Petros,Kathryn Clarke,(unknown),P. Kelly Marcom,Ursula A. Matulonis,L M Parker,(unknown),Eric P. Winer	41

About P. Kelly Marcom

P. Kelly Marcom is a scholar working on Cancer Research, Oncology and Radiology, Nuclear Medicine and Imaging, having authored 49 papers that have together received 1.8k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (22 papers), Cancer Treatment and Pharmacology (13 papers) and Advanced Breast Cancer Therapies (10 papers). The work is most often cited by research in Cancer Research (669 citations), Oncology (1.1k citations) and Reproductive Medicine (149 citations). P. Kelly Marcom has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Eric P. Winer, Harold J. Burstein, Clifford A. Hudis, Jeffrey R. Marks, Peter C. Ungaro, Donald A. Berry, Diana Lake, Hyman B. Muss, Charles L. Shapiro and Lyndsay N. Harris. Their work appears in journals such as JAMA, Journal of Clinical Oncology and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact